文献速递外周动脉疾病

多段外周动脉治疗用药物涂层球囊的研制

Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
PubMed 文献 · J Vasc Surg · 2019-09-10

本研究开发了一种双层涂层的多释放定制医疗器械药物涂层球囊(MR-TMD-DCB),用于单次球囊治疗多个动脉段。体外和体内猪模型显示,单次MR-TMD-DCB可在两个动脉段递送等效且临床相关的药物量。

要点

  • MR-TMD-DCB采用双层涂层,紫杉醇以无定形状态分子分散,颗粒脱落可忽略。
  • 体外流动模型显示单次MR-TMD-DCB向两个离体猪动脉递送相似药量。
  • 体内猪模型第1天和第7天两个动脉段药物摄取和保留量等效且临床相关。

核心结论

  • MR-TMD-DCB可在两个不同动脉段提供等效且临床相关的药物保留水平。
  • 单次MR-TMD-DCB可准确向多个动脉段递送药物。

研究设计与样本

  • 临床前研究:使用双层涂层技术开发MR-TMD-DCB,在cGMP设施中使用预灭菌材料和试剂制备。
  • 体外研究:使用外周动脉流动模型和离体猪动脉分析药物损失、组织摄取和未递送药量。
  • 体内生存研究:健康猪模型,7头猪14次治疗(第1天)测短期药物摄取,7头猪14次治疗(第7天)测药物保留。

主要发现

  • 涂层光滑均匀,紫杉醇以无定形状态分子分散,颗粒脱落可忽略。
  • 体外流动模型:单次MR-TMD-DCB向两个离体动脉递送相似药量(第一动脉707 ± 109 ng/mg,第二动脉783 ± 306 ng/mg)。
  • 体内第1天:两个动脉段药量等效(第一治疗点63 ± 19 ng/mg,第二治疗点59 ± 19 ng/mg)。
  • 体内第7天:两个动脉段药量等效(第一治疗点9 ± 6 ng/mg,第二治疗点10 ± 6 ng/mg)。
  • 各时间点药物水平均在预防新生内膜增生的临床相关范围内。

临床怎么用

  • MR-TMD-DCB可能为多段外周动脉病变提供单次球囊治疗选项,但临床结局需进一步研究。

局限性

  • 研究为临床前动物模型,临床结局需进一步研究。
  • 未来需进行长期药代动力学和安全性研究评估MR-TMD-DCB的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Peripheral artery disease is the second most common cardiovascular disease. It can often occur in complex form when there is a presence of long, diffuse, and multiple lesions. Current treatments use either single long drug-coated balloons (DCBs) or multiple DCBs; however, treatment success is limited. The purpose of this study was to investigate the preclinical feasibility of our multiple-release Tailored Medical Devices DCB (MR-TMD-DCB) to treat multiple arterial segments using a single DCB. METHODS: The MR-TMD-DCBs were developed using a two-layer coating approach. The DCBs were developed in a certified Current Good Manufacturing Practices facility using presterilized materials and reagent and then characterized for coating morphology, thermal and chemical changes, and in vitro particulate shedding. The drug loss, tissue uptake, and undelivered drug amounts were analyzed using an in vitro peripheral artery flow model and explanted pig arteries. Then, an in vivo survival study was performed using a healthy porcine model to measure the short-term drug uptake (seven swine; 14 treatments at day 1) and retention (seven swine; 14 treatments at day 7) in two different arterial segments after treatment with a single MR-TMD-DCB. RESULTS: The coating on the MR-TMD-DCB was smooth and homogeneous with paclitaxel molecularly dispersed in its amorphous state. A negligible number of particulates were shed from the MR-TMD-DCB coating. A similar amount of drug was accurately delivered into two separate explanted arteries using a single MR-TMD-DCB during the in vitro flow model testing (707 ± 109 ng/mg in the first explanted artery and 783 ± 306 ng/mg in the second explanted artery). The MR-TMD-DCB treatment resulted in equivalent drug amounts in the two arterial segments at day 1 (63 ± 19 ng/mg in the first treatment site and 59 ±19 ng/mg in the second treatment site) and at day 7 (9 ± 6 ng/mg in the first treatment site and 10 ± 6 ng/mg in the second treatment site). In addition, the drug levels at each time point were in the clinically relevant range to prevent neointimal hyperplasia. CONCLUSIONS: The MR-TMD-DCBs provided equivalent and clinically relevant drug retention levels into two different arterial segments. Thus, MR-TMD-DCBs can be used to accurately deliver drug into multiple arterial segments with the use of a single DCB. The clinical outcomes of these findings need further investigation. Future long-term pharmacokinetics and safety studies will be performed to evaluate the safety and efficacy of the MR-TMD-DCB.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Anderson JA, Lamichhane S, Fuglsby K, et al. Development of drug-coated balloon for the treatment of multiple peripheral artery segments. J Vasc Surg. 2019. PMID: 31519510. doi:10.1016/j.jvs.2019.04.494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。